Review
Pharmacology & Pharmacy
Nicholas C. Schwier
Summary: Rilonacept is a safe IL-1 trap administered weekly subcutaneously, with proven efficacy in reducing the risk of recurrent pericarditis and promoting clinical response. It may be considered for patients needing weaning from standard background therapy.
ANNALS OF PHARMACOTHERAPY
(2022)
Article
Dermatology
Luca Mastorino, Paolo Dapavo, Sara Susca, Caterina Cariti, Niccolo Siliquini, Anna Verrone, Elena Stroppiana, Michela Ortoncelli, Pietro Quaglino, Simone Ribero
Summary: IL-23 inhibitors showed the best performance in drug survival for patients with psoriasis. IL-17 inhibitors were more effective in the short-term, but anti-IL-23 showed better long-term effectiveness. Male patients and those treated with risankizumab and guselkumab had a lower probability of drug interruption.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT
(2023)
Review
Cardiac & Cardiovascular Systems
Tiffany Dong, Allan L. Klein, Tom Kai Ming Wang
Summary: This review focuses on the pathophysiology, diagnosis, and treatment of recurrent pericarditis, with a particular emphasis on interleukin-1 (IL-1) inhibitors. Recent studies have shown that IL-1 inhibitors, such as anakinra, canakinumab, and rilonacept, have great potential in the treatment of recurrent pericarditis. The RHAPSODY trial found that rilonacept significantly improves pain and inflammation, while reducing recurrence and adverse events. The role of IL-1 inhibitors in the treatment of pericarditis is discussed, along with the introduction of the new IL-1 inhibitor, goflikicept.
CURRENT CARDIOLOGY REPORTS
(2023)
Review
Pharmacology & Pharmacy
Dimitri Poddighe, Micol Romano, Facundo Garcia-Bournissen, Erkan Demirkaya
Summary: Familial Mediterranean fever (FMF) is commonly diagnosed in childhood and is treated predominantly with colchicine, but in cases of intolerance or resistance, the use of biologics, especially interleukin-1 antagonists, should be considered.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2022)
Review
Rheumatology
Naomi Schlesinger, Michael H. Pillinger, Lee S. Simon, Peter E. Lipsky
Summary: This systematic review aimed to assess the effects of interleukin-1 beta (IL-1 beta) inhibitors on gout flares. The results showed that IL-1 beta inhibitors, including canakinumab, anakinra, and rilonacept, were effective in reducing pain and frequency of gout flares, and they were generally well-tolerated. These findings suggest that IL-1 beta inhibitors may be a beneficial and safe alternative for patients with gout flares who cannot tolerate standard therapies.
ARTHRITIS RESEARCH & THERAPY
(2023)
Article
Cardiac & Cardiovascular Systems
Akshay Goel, Dhrubajyoti Bandyopadhyay, Aaqib H. Malik, Rahul Gupta, William H. Frishman, Wilbert S. Aronow
Summary: Pericarditis is a common form of pericardial disease, with a high rate of recurrence despite optimal treatment. IL-1 inhibitors, such as rilonacept, anakinra, and canakinumab, have shown safety and efficacy in treating recurrent pericarditis. However, many questions regarding the duration of treatment and their use in special populations remain unanswered.
CARDIOLOGY IN REVIEW
(2023)
Article
Pharmacology & Pharmacy
Theodora Simopoulou, Sotirios G. Tsiogkas, Efterpi Zafiriou, Dimitrios P. Bogdanos
Summary: In recent years, there has been significant interest in the role of interleukin-17 (IL-17) in promoting proinflammatory immune responses. IL-17, due to its inhibitory effect on immuno-regulation and stimulatory action on inflammation, has become a target for drug development. This review discusses the recent developments in IL-17 inhibitors, such as secukinumab, ixekizumab, bimekizumab, and brodalumab, for the treatment of psoriasis and psoriatic arthritis.
Review
Cardiac & Cardiovascular Systems
Massimo Imazio
Summary: The review discusses recent findings in pericardial diseases, highlighting the potential efficacy of anti-IL-1 agents for corticosteroid-dependent and colchicine-resistant recurrent pericarditis. It suggests that these agents could become a first-line option in future guidelines for cases with systemic inflammation. The treatment of pericardial diseases is gradually becoming more personalized, with consideration of presentation and etiology, and the exploration of new or existing drugs to expand the therapeutic options.
CURRENT CARDIOLOGY REPORTS
(2021)
Article
Dermatology
Martina Kojanova, Jan Hugo, Barbora Velackova, Petra Cetkovska, Jorga Fialova, Tomas Dolezal, Martin Tichy, Spyridon Gkalpakiotis
Summary: This study evaluated the efficacy, safety, and drug survival of IL-17 inhibitors for the treatment of psoriasis. The results showed that all IL-17 inhibitors had significant improvement in the disease scores and quality of life, with good safety profiles. Brodalumab showed the highest effectiveness and drug survival probability.
JOURNAL OF DERMATOLOGICAL TREATMENT
(2022)
Article
Cardiac & Cardiovascular Systems
Massimo Imazio, George Lazaros, Marco Gattorno, Antonio Abbate, Antonio Brucato
Summary: Anakinra is a treatment for idiopathic recurrent pericarditis, acting by blocking IL-1 to control symptoms. Besides local skin injection site reactions, other side effects are rare.
GIORNALE ITALIANO DI CARDIOLOGIA
(2021)
Article
Pharmacology & Pharmacy
Maha Saad, Moqadam Rhamatzada, Susan Chen, Armela Sharra
Summary: Gout, an inflammatory condition caused by elevated serum uric acid concentrations, is managed using nonsteroidal anti-inflammatory drugs, colchicine, or corticosteroids for acute gouty arthritis. Xanthine oxidase inhibitors, uricosuric agents, or a combination of these drugs, along with lifestyle modifications, are needed for preventing gout attacks and treating chronic gout. Allopurinol is a first-line agent for gout prevention in eligible patients, while pegloticase is reserved for those who have failed other treatments. Specialty pharmacists involved in gout management should educate and counsel patients, provide assistance with authorizations, and find ways to minimize treatment costs for patients facing financial barriers.
Review
Rheumatology
Alexander So, Alexandre Dumusc, Sonia Nasi
Article
Rheumatology
Pascal Zufferey, Roxana Valcov, Marion Thomas, Alexandre Dumusc, Marine Forien, Alexander So, Sebastien Ottaviani
Letter
Rheumatology
Alexandre Dumusc, Borbala Pazar Maldonado, Charles Benaim, Pascal Zufferey, Berengere Aubry-Rozier, Alexander So
Meeting Abstract
Rheumatology
K. Cunha Rodrigues, A. Grosjean, T. Hugle, A. Dumusc
ANNALS OF THE RHEUMATIC DISEASES
(2021)
Meeting Abstract
Medicine, General & Internal
A. Dumusc, F. Valerio, T. Hugle
SWISS MEDICAL WEEKLY
(2020)
Meeting Abstract
Medicine, General & Internal
A. Schlapfer-Pessina, P. Maeder, V Dunet, S. La Rosa, A. Dumusc
SWISS MEDICAL WEEKLY
(2020)
Meeting Abstract
Medicine, General & Internal
P. Zufferey, L. Orlik, A. Dumusc
SWISS MEDICAL WEEKLY
(2020)
Meeting Abstract
Rheumatology
A. Dumusc, F. Valerio, T. Hugle
ANNALS OF THE RHEUMATIC DISEASES
(2020)
Meeting Abstract
Medicine, General & Internal
A. Dumusc, F. Valerio, F. Becce, C. Sempoux, D. Dan
SWISS MEDICAL WEEKLY
(2019)
Meeting Abstract
Medicine, General & Internal
A. Dumusc, B. Bannert, D. Dan, T. Hugle
SWISS MEDICAL WEEKLY
(2019)
Meeting Abstract
Medicine, General & Internal
A. Dumusc, T. Hugle, P. Zufferey
SWISS MEDICAL WEEKLY
(2019)
Meeting Abstract
Rheumatology
Alexandre Dumusc, Thomas Huegle, Pascal Zufferey
ANNALS OF THE RHEUMATIC DISEASES
(2019)
Meeting Abstract
Rheumatology
Alexandre Dumusc, Bettina Bannert, Diana Dan, Thomas Huegle
ANNALS OF THE RHEUMATIC DISEASES
(2019)
Meeting Abstract
Rheumatology
Benjamin Fisher, Francesca Barone, Kerry Jobling, Peter Gallagher, Victoria Macrae, Andrew Filby, Gillian Hulmes, Paul Milne, Emmanuella Traianos, Valentina Iannizzotto, Alexandre Dumusc, Simon J. Bowman, Jessica Tarn, Dennis Lendrem, Daniel Burge, James Posada, Wan-fai Ng
ANNALS OF THE RHEUMATIC DISEASES
(2019)